PMID- 20065053
OWN - NLM
STAT- MEDLINE
DCOM- 20100531
LR  - 20211020
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Print)
IS  - 0066-4804 (Linking)
VI  - 54
IP  - 3
DP  - 2010 Mar
TI  - Amodiaquine dosage and tolerability for intermittent preventive treatment to 
      prevent malaria in children.
PG  - 1265-74
LID - 10.1128/AAC.01161-09 [doi]
AB  - Sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) is a highly efficacious 
      regimen for intermittent preventive treatment to prevent malaria in children 
      (IPTc), but the amodiaquine component is not always well tolerated. We determined 
      the association between amodiaquine dosage by body weight and mild adverse events 
      (AEs) and investigated whether alternative age-based regimens could improve 
      dosing accuracy and tolerability, using data from two trials of IPTc in Senegal, 
      one in which AQ dose was determined by age and the other in which it was 
      determined by weight category. Both dosage strategies resulted in some children 
      receiving AQ doses above the recommended therapeutic range. The odds of vomiting 
      increased with increasing amodiaquine dosage. In one study, incidence of fever 
      also increased with increasing dosage. Anthropometric data from 1,956 children 
      were used to predict the dosing accuracy of existing and optimal alternative 
      regimens. Logistic regression models describing the probability of AEs by dosage 
      were used to predict the potential reductions in mild AEs for each regimen. 
      Simple amendments to current AQ dosing schedules based on the child's age could 
      substantially increase dosing accuracy and thus improve the tolerability of IPTc 
      using SP-amodiaquine in situations where weighing the child is impractical.
FAU - Cairns, M
AU  - Cairns M
AD  - Infectious Disease Epidemiology Unit, London School of Hygiene and Tropical 
      Medicine, Keppel Street, London WC1E 7HT, United Kingdom. 
      matthew.cairns@lshtm.ac.uk
FAU - Cisse, B
AU  - Cisse B
FAU - Sokhna, C
AU  - Sokhna C
FAU - Cames, C
AU  - Cames C
FAU - Simondon, K
AU  - Simondon K
FAU - Ba, E H
AU  - Ba EH
FAU - Trape, J-F
AU  - Trape JF
FAU - Gaye, O
AU  - Gaye O
FAU - Greenwood, B M
AU  - Greenwood BM
FAU - Milligan, P J M
AU  - Milligan PJ
LA  - eng
GR  - G0700837/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100111
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Antimalarials)
RN  - 0 (Drug Combinations)
RN  - 220236ED28 (Amodiaquine)
RN  - 37338-39-9 (fanasil, pyrimethamine drug combination)
RN  - 88463U4SM5 (Sulfadoxine)
RN  - Z3614QOX8W (Pyrimethamine)
SB  - IM
MH  - Age Factors
MH  - Amodiaquine/*administration & dosage/adverse effects
MH  - Antimalarials/*administration & dosage/adverse effects
MH  - Body Weight
MH  - Child
MH  - Child, Preschool
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Infant
MH  - Malaria/*prevention & control
MH  - Pyrimethamine/*administration & dosage/adverse effects
MH  - Seasons
MH  - Sulfadoxine/*administration & dosage/adverse effects
MH  - Treatment Outcome
PMC - PMC2825997
EDAT- 2010/01/13 06:00
MHDA- 2010/06/01 06:00
PMCR- 2010/01/11
CRDT- 2010/01/13 06:00
PHST- 2010/01/13 06:00 [entrez]
PHST- 2010/01/13 06:00 [pubmed]
PHST- 2010/06/01 06:00 [medline]
PHST- 2010/01/11 00:00 [pmc-release]
AID - AAC.01161-09 [pii]
AID - 1161-09 [pii]
AID - 10.1128/AAC.01161-09 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 2010 Mar;54(3):1265-74. doi: 10.1128/AAC.01161-09. 
      Epub 2010 Jan 11.